Other Dyslipidemia Drugs

• Bempedoic Acid Indication Update - Dec 07, 2023
• PCSK9 Modulators - Aug 04, 2022
• Non-Statin Dyslipidemia Drugs - Aug 05, 2021

• Non-statin Dyslipidemia Drugs - Aug 06, 2020
• Non-statin Lipid Lowering Agents - May 23, 2019
• PCSK9 Inhibitors - Jan 25, 2018
• Non-statin Lipid-lowering Agents - Nov 17, 2016
• PCSK9 Inhibitors - Nov 19, 2015
• Other Lipotropics - Sep 23, 2014
• Omega-3 Fatty Acids Prior Authorization Criteria - Mar 27, 2014
• Fish Oil Class Review - Jan 30, 2014
• Class Update: Other Lipid Lowering Agents - Sep 26, 2013
• Abbreviated Class Review: Non-Statin Lipid Lowering Agents - May 31, 2012

• Kynampro (mipomersen) and Juxtapid (lomitapide) - May 26, 2016

• August 2022 - An Update in Lipid Lowering Therapies
• March 2019 - Non-statin Low-Density Lipoprotein Cholesterol (LDL-C) Lowering Therapy and Cardiovascular Outcomes
• May 2014 - New Cholesterol Guidelines: A Significant Shift in Cholesterol Management

• March 2014 - Evidence Based Review of Fish Oil: Going Beyond the Headlines

Y = preferred
N = non-preferred. Non-preferred drugs listed as N but without clinical drug use criteria are subject to the Non-Preferred Drugs in Select PDL Classes prior authorization criteria. New drugs will be listed as N until reviewed by the P&T Committee and are subject to the New Drug Policy.
V = voluntary non-preferred. Non-preferred mental health drugs are listed as V and prior authorization is not required.
Null (i.e. blank) = indicates the class or specific drug has not been reviewed for PDL placement.